Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avastin + Radiation + Temozolomide followed by Avastin + Temozolomide + Irinotecan for GBM and Gliosarcoma
NCT00597402Phase 2Completed
- Sponsor
- Duke University
- Start
- Jul 2007
- Primary completion
- Aug 2011
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab and irinotecan in glioblastoma (GBM) and Gliosarcoma (GS), sponsored by Duke University. Primary endpoint: Overall Survival at 16 months. Started Jul 2007; status: completed.
02
Drugs
bevacizumabirinotecan
03
Conditions
glioblastoma (GBM)Gliosarcoma (GS)
Beyond the preview
Go deeper on NCT00597402.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00597402.